CA2227871A1 - Apport de polynucleotides dans les muqueuses - Google Patents

Apport de polynucleotides dans les muqueuses Download PDF

Info

Publication number
CA2227871A1
CA2227871A1 CA002227871A CA2227871A CA2227871A1 CA 2227871 A1 CA2227871 A1 CA 2227871A1 CA 002227871 A CA002227871 A CA 002227871A CA 2227871 A CA2227871 A CA 2227871A CA 2227871 A1 CA2227871 A1 CA 2227871A1
Authority
CA
Canada
Prior art keywords
polynucleotide
composition
animal
binding protein
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002227871A
Other languages
English (en)
Inventor
Dannie H. King
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maxim Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2227871A1 publication Critical patent/CA2227871A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

On décrit une composition d'apport d'un polynucléotide à des cellules de muqueuses, des cellules neurales ou autres, laquelle comprend une association d'une protéine de liaison de GM1 et d'un polynucléotide. On décrit également un procédé de modulation de l'immunité, consistant à administrer ladite composition à un animal et à faire s'exprimer le polynucléotide dans l'animal, ce qui permet à ce dernier de produire une réponse immune au produit du polynucléotide. On décrit encore une méthode de thérapie génique consistant à administrer à un animal une protéine de liaison du GM1 ainsi qu'un polynucléotide fonctionnel et à faire s'exprimer le polynucléotide dans l'animal, la fonction du polynucléotide exerçant ainsi sur l'animal un effet thérapeutique.
CA002227871A 1995-07-26 1996-07-19 Apport de polynucleotides dans les muqueuses Abandoned CA2227871A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US152795P 1995-07-26 1995-07-26
US60/001,527 1995-07-26
PCT/US1996/012041 WO1997005267A2 (fr) 1995-07-26 1996-07-19 Apport de polynucleotides dans les muqueuses

Publications (1)

Publication Number Publication Date
CA2227871A1 true CA2227871A1 (fr) 1997-02-13

Family

ID=21696500

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002227871A Abandoned CA2227871A1 (fr) 1995-07-26 1996-07-19 Apport de polynucleotides dans les muqueuses

Country Status (5)

Country Link
EP (1) EP0840796A2 (fr)
JP (1) JPH11510164A (fr)
AU (1) AU6505796A (fr)
CA (1) CA2227871A1 (fr)
WO (1) WO1997005267A2 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6553398A (en) * 1997-03-12 1998-09-29 Hybridon, Inc. Down-regulation of gene expression by colorectal administration of synthetic oligonucleotides
GB9713122D0 (en) * 1997-06-20 1997-08-27 Chiron Spa Novel method of DNA transfer into cells
PT1117435E (pt) * 1998-09-30 2008-02-21 Us Gov Univ Health Sciences Holotoxina da cólera mutante como adjuvante
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
US7041296B1 (en) * 1999-11-12 2006-05-09 The United States Of America As Represented By The Department Of Health And Human Services Methods of treating inflammatory bowel disease using cholera toxin B subunit
AU2002346249B2 (en) 2001-06-07 2007-03-15 The Regents Of The University Of Colorado Mutant Forms of Cholera Holotoxin as an Adjuvant
US7332174B2 (en) 2001-06-07 2008-02-19 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
JP2005526769A (ja) * 2002-03-15 2005-09-08 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 治療剤を全身搬送するための中央気道投与
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
ES2442024T3 (es) 2008-07-15 2014-02-07 Academia Sinica Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
WO2014031498A1 (fr) 2012-08-18 2014-02-27 Academia Sinica Sondes perméables aux cellules pour l'identification et l'imagerie de sialidases
EP3013365B1 (fr) 2013-06-26 2019-06-05 Academia Sinica Antigènes rm2 et leur utilisation
EP3013347B1 (fr) 2013-06-27 2019-12-11 Academia Sinica Conjugués de glycane et leur utilisation
JP6486368B2 (ja) 2013-09-06 2019-03-20 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
AU2015206370A1 (en) 2014-01-16 2016-07-07 Academia Sinica Compositions and methods for treatment and detection of cancers
CN106415244B (zh) 2014-03-27 2020-04-24 中央研究院 反应性标记化合物及其用途
CA2950415A1 (fr) 2014-05-27 2015-12-03 Academia Sinica Glycoanticorps anti-cd20 et leurs utilisations
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CN106661099A (zh) 2014-05-27 2017-05-10 中央研究院 抗her2醣抗体及其用途
JP7093612B2 (ja) 2014-05-27 2022-06-30 アカデミア シニカ Ｂａｃｔｅｒｏｉｄｅｓ由来のフコシダーゼおよびそれを使用する方法
WO2015184001A1 (fr) 2014-05-28 2015-12-03 Academia Sinica Glycoanticorps anti-thf-alpha et leurs utilisations
TWI745275B (zh) 2014-09-08 2021-11-11 中央研究院 使用醣脂激活人類ｉＮＫＴ細胞
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
JP6779887B2 (ja) 2015-01-24 2020-11-04 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 新規なグリカンコンジュゲートおよびその使用方法
EP3426693A4 (fr) 2016-03-08 2019-11-13 Academia Sinica Procédés de synthèse modulaire de n-glycanes et de puces à n-glycanes
CA3034057A1 (fr) 2016-08-22 2018-03-01 CHO Pharma Inc. Anticorps, fragments de liaison, et procedes d'utilisation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78775A (en) * 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
JPS63258493A (ja) * 1987-04-15 1988-10-25 Mitsui Toatsu Chem Inc 抗ガングリオシドｇｍ↓１単クロ−ン性抗体、これを産生する細胞及びこれから成る試薬
PT92511A (pt) * 1988-12-07 1990-06-29 Univ Leicester Processo de preparacao de um hospedeiro transformado e de proteinas de fusao da subunidade b de toxina labil ao calor
DE69005572T2 (de) * 1989-09-08 1994-04-07 Takeda Chemical Industries Ltd Fusionsproteine und Herstellung davon.
IL96475A0 (en) * 1989-11-29 1991-08-16 Innovative Tech Center Chimeric proteins
US5433946A (en) * 1991-10-11 1995-07-18 Health Research Inc. Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5972336A (en) * 1992-11-03 1999-10-26 Oravax Merieux Co. Urease-based vaccine against helicobacter infection
GB2292887B (en) * 1993-04-16 1997-05-07 Univ Portsmouth Enterprise Drug delivery system
US5681571A (en) * 1993-10-08 1997-10-28 Duotol Ab Immunological tolerance-inducing agent

Also Published As

Publication number Publication date
EP0840796A2 (fr) 1998-05-13
JPH11510164A (ja) 1999-09-07
WO1997005267A2 (fr) 1997-02-13
AU6505796A (en) 1997-02-26
WO1997005267A3 (fr) 1997-04-24

Similar Documents

Publication Publication Date Title
CA2227871A1 (fr) Apport de polynucleotides dans les muqueuses
US5830877A (en) Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US5985847A (en) Devices for administration of naked polynucleotides which encode biologically active peptides
CA2169635C (fr) Methode, compositions et dispositifs pour administrer des polynucleotides nus codant des peptides biologiquement actifs
Hagino et al. GALA-modified lipid nanoparticles for the targeted delivery of plasmid DNA to the lungs
CA2425745C (fr) Expression des sequences polynocleotides exogenes chez un vertebre
US20220090074A1 (en) Hnf4a sarna compositions and methods of use
US20170044540A1 (en) Sarna compositions and methods of use
Nakamura et al. Lipid nanoparticles fuse with cell membranes of immune cells at low temperatures leading to the loss of transfection activity
CN114788876B (zh) 治疗糖尿病的mRNA药物制剂及其制备方法与应用
JP2003530360A (ja) 薬剤送達のためのペプチド複合体
US10206976B2 (en) Protein particles comprising disulfide crosslinkers and uses related thereto
US7741431B2 (en) Liposomes containing novel targeting and/or fusogenic peptides, preparations containing them and therapeutic use thereof
Kaminski et al. Immunotherapy and prostate cancer
JP2001526181A (ja) 遺伝子輸送体であるグラフト共重合体
CN113354726B (zh) 乳铁蛋白活性肽及其应用
US7592320B2 (en) Cancer gene therapy based on translational control of a suicide gene
Kanazawa et al. Effective vaginal DNA delivery with high transfection efficiency is a good system for induction of higher local vaginal immune responses
US20240175033A1 (en) TMEM173 saRNA Compositions and Methods of Use
CN111481677A (zh) 血脑屏障渗透性调控剂及其应用
AU3789099A (en) Myelin basic protein peptides and uses thereof
US8679780B2 (en) Method of reducing immunological tolerance to malignancy
JPH09324000A (ja) インターロイキン−２受容体を特異的に認識する因子とリボヌクレアーゼとの接合体
WO2024165876A2 (fr) Compositions et procédés d'utilisation de saarn c/ebp alpha
KR101208994B1 (ko) 세포 투과성 ｒｐＳ3 융합 단백질을 포함하는 염증 예방 및 치료용 조성물

Legal Events

Date Code Title Description
FZDE Dead